Toripalimab Plus Chemotherapy as Second-Line Treatment in Previously EGFR-TKI Treated Patients With EGFR-Mutant-Advanced NSCLC: A Multicenter Phase-II Trial

Last Updated: Monday, November 29, 2021

This multicenter phase-II trial aimed to investigate the efficacy, safety, and predictive biomarkers of toripalimab plus chemotherapy as second-line treatment in patients with EGFR-mutant-advanced NSCLC. Toripalimab plus chemotherapy showed promising anti-tumor activity with acceptable safety profiles as the second-line setting in patients with EGFR-mutant NSCLC.

Signal Transduction and Targeted Therapy

Translational Lung Cancer Research

Neoadjuvant Treatment of Stage IIIA-N2 in EGFR-Mutant/ALK-Rearranged Non–Small Cell Lung Cancer

Journal of Thoracic Oncology

Biomarker Discovery and Validation: Statistical Considerations

Lung Cancer

Biomarker Testing in Non-Small Cell Lung Cancer in Routine Care: Analysis of the First 3,717 Patients in the German Prospective, Observational, Nation-Wide CRISP Registry (AIO-TRK-0315)

Journal of Clinical Oncology

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

European Journal of Cancer

COVID-19 in Lung Cancer Patients Receiving ALK/ROS1 Inhibitors

Translational Lung Cancer Research

Emerging Biomarkers for Neoadjuvant Immune Checkpoint Inhibitors in Operable Non–Small Cell Lung Cancer

New England Journal of Medicine

Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer

The ASCO Post

FDA Grants Accelerated Approval to Mobocertinib for Patients With Metastatic NSCLC and EGFR Exon 20 Insertion Mutations

International Association for the Study of Lung Cancer

Perceptions of Biomarker Testing for Underserved Patients With Lung Cancer: A Mixed-Methods Survey of US-Based Oncology Clinicians

Frontiers in Oncology

A Retrospective Study of Brain Metastases From Solid Malignancies: The Effect of Immune Checkpoint Inhibitors

Biomarkers in NSCLC Resource Center

Toripalimab Plus Chemotherapy as Second-Line Treatment in Previously EGFR-TKI Treated Patients With EGFR-Mutant-Advanced NSCLC: A Multicenter Phase-II Trial

Translational Lung Cancer Research

Neoadjuvant Treatment of Stage IIIA-N2 in EGFR-Mutant/ALK-Rearranged Non–Small Cell Lung Cancer

Journal of Thoracic Oncology

Biomarker Discovery and Validation: Statistical Considerations

Lung Cancer

Biomarker Testing in Non-Small Cell Lung Cancer in Routine Care: Analysis of the First 3,717 Patients in the German Prospective, Observational, Nation-Wide CRISP Registry (AIO-TRK-0315)

Journal of Clinical Oncology

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

European Journal of Cancer

COVID-19 in Lung Cancer Patients Receiving ALK/ROS1 Inhibitors

Translational Lung Cancer Research

Emerging Biomarkers for Neoadjuvant Immune Checkpoint Inhibitors in Operable Non–Small Cell Lung Cancer

New England Journal of Medicine

Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer

The ASCO Post

FDA Grants Accelerated Approval to Mobocertinib for Patients With Metastatic NSCLC and EGFR Exon 20 Insertion Mutations

International Association for the Study of Lung Cancer

Perceptions of Biomarker Testing for Underserved Patients With Lung Cancer: A Mixed-Methods Survey of US-Based Oncology Clinicians

Frontiers in Oncology

A Retrospective Study of Brain Metastases From Solid Malignancies: The Effect of Immune Checkpoint Inhibitors

Fast Facts #12: Choosing/Sequencing Therapy